Immunic News

Hold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial Outlook

TipRanksMay 10 13:26

Immunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 9 22:23

Immunic | 10-Q: Quarterly report

Futu NewsMay 8 19:23 · Announcements

Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche

Immunic Says It Bolstered Balance Sheet Through Three-tranche Private Placement Totaling Up To $240M, Extending Cash Runway Into Q3 2025, Based On Initial $80M Tranche

BenzingaMay 8 18:53

Immunic: Q1 Earnings Snapshot

BarchartMay 8 18:36

Immunic Q1 EPS $(0.30) Misses $(0.26) Estimate, Cash And Equivalents As Of March 31, 2024 Were $97.3M

Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 48.28 percent increase over losses of $(0.58) pe

BenzingaMay 8 18:33

Press Release: Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire NEW YORK, May 8, 2024 -- Substantially Bolstered Balance Sheet Through a Three-Tranche Private P

Dow JonesMay 8 18:30

Immunic 1Q Loss $29.6M >IMUX

Immunic 1Q Loss $29.6M >IMUX

Dow JonesMay 8 18:30

Immunic 1Q Loss/Shr 30c >IMUX

Immunic 1Q Loss/Shr 30c >IMUX

Dow JonesMay 8 18:30

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

Stockhouse May 8 18:30

Immunic Advances 'potentially Groundbreaking' MS Therapy Vidofludimus Calcium During Q1 | NASDAQ:IMUX

Proactive InvestorsMay 8 17:35

Immunic Advances 'potentially Groundbreaking' MS Therapy Vidofludimus Calcium | NASDAQ:IMUX

Proactive InvestorsMay 8 17:35

Immunic to Participate in Investor and Scientific Conferences in May

NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory an

PR NewswireMay 6 18:30

Immunic Phase 2 EMPhASIS Trial Data Highlighted in Peer-reviewed Neurology Journal

Yahoo FinanceMay 1 22:02

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...

PR NewswireMay 1 18:30

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation

30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks.Improvements in Serum Neurofilament Lig

BenzingaApr 30 18:32

Immunic CEO Dr Daniel Vitt Marks International Day of Immunology With Discussion on Its Crucial Role

Yahoo FinanceApr 29 23:11

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)

TipRanksApr 16 14:50

Top 10 Stocks With Upwards and Downwards Daily Percentage Change - Piper Sandler

Seeking AlphaApr 12 23:34

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)

TipRanksApr 10 19:20